BenevolentAI SPAC Presentation Deck

Multiple value inflection milestones in the near future BEN-2293 (Atopic Dermatitis) BEN-8744 (Ulcerative Colitis) AZ Collaboration Pipeline depth and progression Other Platform Collaborations Late 2021 Phase I/II Part A completes H1 2022 Candidate nominated for IND-Enabling Studies in Sep 12 programmes named (Chemistry and beyond) Phase I/II Part B completes in mid 2022 H2 2022 I Exploratory discussions with a number of parties underway Asset ready for Out-licensing Further targets selected and existing targets advanced over time period CTA filed by late 2022 6 new targets added to the pipeline Up to 3 assets enter IND-enabling studies 2023+ Phase I starts early 2023 5+ INDS per year from 2024 onwards Benevolent 38

View entire presentation